STOCK TITAN

Iveric Bio to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

IVERIC bio (Nasdaq: ISEE) will have its President, Pravin U. Dugel, M.D., participate in a panel on Ophthalmic Gene Therapy at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11 at 8:00 a.m. ET. The event is open to investors and the public via live webcast on the company's website, with an archived replay available for 30 days thereafter. Iveric bio focuses on developing treatments for retinal diseases, with both therapeutic and gene therapy product candidates addressing significant unmet medical needs.

Positive
  • None.
Negative
  • None.

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in the panel discussion, “Only Have Eyes For You - Ophthalmic Gene Therapy,” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11 at 8:00 a.m. Eastern Time.

Investors and the general public are invited to listen to a live webcast on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the on-demand panel discussion will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.

About Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release. Iveric Bio anticipates that subsequent events and developments will cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so.

ISEE-G

FAQ

What is the date and time of IVERIC bio's panel discussion at the Wedbush PacGrow Healthcare Conference?

The panel discussion will take place on August 11 at 8:00 a.m. ET.

Where can I watch the IVERIC bio panel discussion on Ophthalmic Gene Therapy?

The panel discussion will be available via live webcast on IVERIC bio's website.

What is the focus of IVERIC bio as a biopharmaceutical company?

IVERIC bio focuses on discovering and developing novel treatment options for retinal diseases.

How long will the archived replay of the IVERIC bio panel discussion be available?

The archived replay will be available for at least 30 days after the conference.

Who will represent IVERIC bio at the Wedbush PacGrow Healthcare Conference?

Pravin U. Dugel, M.D., President of IVERIC bio, will participate in the panel discussion.

ISEE

NASDAQ:ISEE

ISEE Rankings

ISEE Latest News

ISEE Stock Data

5.51B
136.61M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York